Laura Francis

October 16, 2026

Truist Securities raises SI-BONE price target to $25. Truist Securities kept its existing rating on SI‑BONE and lifted its price target to $25. The new target sits near the midpoint of the nine‑analyst consensus range of $20 to $32, and slightly above the current 52‑week high of $21.89. This adjustment suggests the firm sees further upside potential for the company.

October 17, 2026

BRKR risk highlighted in recent market analysis. A recent article discusses why Bruker (BRKR) is considered risky, suggesting alternative stocks. This commentary focuses on the parent company's common stock, which may influence sentiment for its preferred shares. The preferred stock has a low dividend yield and trades within a wide 52-week range.